Two-Year Follow-Up Analysis of Telaprevir-Based Antiviral Triple Therapy for HCV Recurrence in Genotype 1 Infected Liver Graft Recipients as a First Step towards Modern HCV Therapy

Table 1

Patient characteristics at baseline.

	Included patient population for TVR/PegIFN/RBV triple therapy ()
Age (years), mean ± SD	51.8 ± 10.5
Gender (male)	7 (58%)
Body mass index (kg/m^2), mean ± SD	26.4 ± 5.3
HCV genotype
1a	2 (17%)
1b	10 (83%)
Previous PegIFN/RBV therapy after OLT
Naive	5 (42%)
Nonresponder/relapsers	7 (58%)
Time between OLT and beginning TVR/PegIFN/RBV therapy (months), mean ± SD	63.7 ± 61.4
Fibrosis grade
1	4 (33%)
2	5 (42%)
3	3 (25%)
HCV viral load (log 10 IU/mL), mean ± SD	6.1 ± 0.8
Bilirubin (μmol/L), mean ± SD	23.9 ± 13.7
ALT (μkat/L), mean ± SD	0.99 ± 0.84
Glomerular filtration rate (mL/min/1.73 m^2), mean ± SD	72.0 ± 20.4
Hemoglobin (mmol/L), mean ± SD	7.33 ± 1.43
White blood cell count (/nL), mean ± SD	4.8 ± 1.9
Platelet count (/nL), mean ± SD	222.3 ± 105.9